Anti-phospholipid syndrome: Current opinion on mechanisms involved, laboratory characterization and diagnostic aspects

Amiral, Jean; Peyrafitte, Marie; Dunois, Claire; Vissac, Anne Marie; Seghatchian, Jerard

doi:10.1016/j.transci.2017.07.014

Cited by 11 publications

(10 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This syndrome can occur alone (primary APS) or may be associated with other existing connective diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome, certain infections, etc. 3,4 Estimates have indicated that the incidence of APS is around 5 new cases per 100,000 individuals per year and the prevalence around 40-50 cases per 100,000 persons. 5 Thrombotic events are one of the prominent clinical features of APS, which may occur in virtually any blood vessel.…”

Section: Introductionmentioning

confidence: 99%

Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients With Antiphospholipid Syndrome: A Single-Center Retrospective Study

Shen

Huang

Fan

2021

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) with cerebral venous sinus thrombosis (CVST) is a relatively rare phenomenon, and this observational study aimed to investigate the clinical characteristics of APS patients complicated with CVST. We retrospectively investigated the clinical characteristics of CVST events in APS and compared differential characteristics and associated factors between APS patients with and without CVST. Twenty-one CVST patients with APS were enrolled including 14 females (9.4%) and 7 males (5.8%). The median age and disease duration at onset of CVST was 33 years (IQR 28-48) old and 1.3 months (IQR 0.7-4), respectively. Among APS patients with CVST, 12 (57.1%) cases presented with neurologic symptoms of CVST as the initial manifestation. Onset of CVST was mainly chronic (52.4%). Headache (90.5%) was the most common neurological symptom. The common locations of CVST were transverse sinus (76.2%) and superior sagittal sinus (57.1%), with more frequently (76.2%) dual or multiple sinuses involved. All patients with CVST were treated with anticoagulant, and 5 (23.8%) patients received endovascular therapy. Sixteen (84.2%) patients had good outcomes and 3 (15.8%) patients died at last follow-up. There were no significant differences ( P > 0.05) between two groups in the analysis of related APS indicators. There were no significant differences ( P > 0.05) between two groups in the analysis of related APS indicators. Although APS complicated with CVST is rare and predominately chronic developed. The evaluation of CVST should be performed for APS patients with intracranial hypertension syndrome. The routine screening of antiphospholipid antibodies (aPLs) is highly recommended in unexplained CVST patients. Most CVST patients with APS will have a good prognosis after treatment, and endovascular therapy is an alternative treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients With Antiphospholipid Syndrome: A Single-Center Retrospective Study

Shen

Huang

Fan

2021

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…LA testing is part of a laboratory panel for thrombophilia investigations because patients with LA have an increased risk for both arterial and venous thrombosis. [9][10][11] The most commonly used LA test is the dilute Russell viper venom time (dRVVT). The reagent contains a factor X activating (FXa) enzyme, the resultant FXa then forms the phospholipid-dependent prothrombinase assembly to generate thrombin, and the clotting time is registered.…”

Section: Introductionmentioning

confidence: 99%

“…This interference also includes laboratory testing for lupus anticoagulant (LA) antibodies, a specific class of antiphospholipid antibodies that are prothrombotic in nature. LA testing is part of a laboratory panel for thrombophilia investigations because patients with LA have an increased risk for both arterial and venous thrombosis 9‐11 …”

Section: Introductionmentioning

confidence: 99%

Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays

Hillarp

Strandberg

Gustafsson

et al. 2020

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…LA is usually detected with clotting assays based on aPTT and dRVVT. Both can be performed at low and high phospholipid concentration, or on 1:1 mixtures of tested sample and a normal plasma pool (10). Some prothrombin assays have demonstrated to be sensitive to the effects of LA, leading to a prolonged PT and consequently false INR values.…”

Section: Lupus Anticoagulantmentioning

confidence: 99%

Lupus Antibody Mimicking Reduced Plasmatic Coagulation in a Patient With Atrial Fibrillation and Ischemic Stroke

et al. 2020

View full text Add to dashboard Cite

show abstract

Anti-phospholipid syndrome: Current opinion on mechanisms involved, laboratory characterization and diagnostic aspects

Cited by 11 publications

References 79 publications

Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients With Antiphospholipid Syndrome: A Single-Center Retrospective Study

Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients With Antiphospholipid Syndrome: A Single-Center Retrospective Study

Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays

Lupus Antibody Mimicking Reduced Plasmatic Coagulation in a Patient With Atrial Fibrillation and Ischemic Stroke

Contact Info

Product

Resources

About